Belite Bio Announces Positive Topline Phase III DRAGON Results for Tinlarebant
Belite Bio reported positive topline Phase III DRAGON results for tinlarebant in Stargardt disease, citing efficacy signals, a tolerable safety profile and plans for regulatory review.
Seeking Alpha
2 min read
Stocks
Biotechnology
Clinical Trials